Compare Peptides
Select any two compounds for a side-by-side comparison of mechanism, uses, risks, and FDA regulatory status.
Popular comparisons
A synthetic octapeptide analog of somatostatin with a much longer half-life than the natural hormone. FDA-approved for acromegaly, carcinoid tumors, and VIPomas. One of the foundational peptide drugs in endocrinology.
A synthetic analog of growth hormone-releasing hormone (GHRH) that stimulates the pituitary gland to produce more growth hormone. Available with or without a Drug Affinity Complex (DAC) that extends its half-life.
Binds to somatostatin receptors (primarily SSTR2 and SSTR5), inhibiting growth hormone, glucagon, and insulin secretion. Reduces splanchnic blood flow and inhibits GI motility and secretion.
Binds to GHRH receptors on the pituitary gland, stimulating pulsatile release of growth hormone. The DAC version binds to albumin in the blood, extending the half-life from minutes to approximately 6-8 days.
- Acromegaly
- Carcinoid syndrome
- VIPomas
- GI bleeding (variceal)
- Dumping syndrome
- Growth hormone optimization
- Improved sleep quality
- Fat loss
- Muscle recovery
- Anti-aging protocols
- Gallstones (common with long-term use)
- GI side effects (diarrhea, nausea)
- Hyperglycemia or hypoglycemia
- Injection site pain
- Bradycardia
- Water retention
- Tingling or numbness
- Potential cortisol elevation
- Limited long-term safety data
- May affect blood sugar levels
FDA-approved as Sandostatin (1988, subcutaneous) and Sandostatin LAR (1998, monthly depot). Generic octreotide available. Widely used in endocrinology and oncology.
Reclassified to Category 1 in February 2026 as part of the HHS announcement restoring compounding access. Not affected by the April 15, 2026 Category 2 removal action. Available through licensed 503A compounding pharmacies with a physician prescription.
- Octreotide in the treatment of acromegaly
1990 · PubMed
This comparison is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before starting any peptide therapy.